Venetoclax with azacitidine or low dose cytarabine as an alternative to intensive chemotherapy in fit adults during the COVID19 pandemic: real world data from the UK National Health Service
Authors
Othman, J.Amer, M.
Amofa, R.
Laura, A.
Austin, M. J.
Bashford, A.
Belsham, E.
Boot, J.
Campbell, V. L.
Coats, T.
Collins, A.
Crawley, C.
Crolla, F.
Cross, J. W.
Dalley, C.
Dang, R.
Dennis, M.
Dhawan, S.
Elliott, Johnathon
Galli, S.
Gallipoli, P.
Hodgson, K.
Jain, M.
Kalkur, P.
Katsomitrou, V.
Khan, A.
Khwaja, A.
Krishnamurthy, P.
Latif, A.
Laurie, J.
Lim, M.
Loizou, E.
Loke, J.
Mannari, D.
Manson, C.
Marshall, S. R.
Mobashwera, B.
Murthy, V.
Ochaya, O.
Orthi, S.
Palanicawandar, R.
Pillai, S.
Radzova, D.
Rye, A.
Saunders, J.
Smith, M.
Taussig, D.
Taylor, T.
Whitmill, R.
Zhao, R.
Freeman, S. D.
Craddock, C.
Dillon, R.
Affiliation
Department of Medical and Molecular Genetics, King's College, LondonIssue Date
2021
Metadata
Show full item recordCitation
Othman J, Amer M, Amofa R, Laura A, Austin MJ, Bashford A, et al. Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413901053.Journal
BloodDOI
10.1182/blood-2021-149685Additional Links
https://dx.doi.org/10.1182/blood-2021-149685Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-149685